VIP

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and neuroprotective properties. Acting through VPAC1 and VPAC2 receptors, VIP regulates immune function, vascular tone, circadian rhythms, and neurological health. It has been extensively studied for chronic inflammatory response syndrome (CIRS), pulmonary conditions, autoimmune diseases, and most recently COVID-19 respiratory failure. The injectable form (Aviptadil/Zyesami) received FDA Fast Track designation for COVID-19 ARDS.

• CIRS (Mold/Biotoxin Illness)
• Autoimmune Disease
• Respiratory Inflammation

Immune regulation and reduced inflammation, neuroprotection and circadian rhythm support, respiratory health improvement, direct CNS delivery bypassing BBB, correction of CIRS inflammatory markers, potential cognitive and mood benefits.

VIP binds to VPAC1 and VPAC2 receptors coupled to Gαs proteins, activating adenylate cyclase and increasing cAMP/PKA signaling. This leads to anti-inflammatory effects through inhibition of pro-inflammatory cytokines (IL-6, TNF-α), modulation of T helper cell differentiation, and regulation of innate and adaptive immune responses. Intranasal delivery allows direct brain access via olfactory and trigeminal pathways.

Peak plasma concentration: 15 min. Elimination half-life: 30 min. Largely cleared by: ~2.5 hrs.

Research protocols from published literature — not dosing recommendations.

• BPC-157 — Compatible: Complementary anti-inflammatory mechanisms - VIP modulates immune response while BPC-157 promotes tissue healing
• Thymosin Alpha-1 — Synergistic: Both are immunomodulatory peptides that may complement each other in regulating immune function
• LL-37 — Compatible: Different mechanisms - VIP is anti-inflammatory while LL-37 is antimicrobial. May work together in CIRS protocols
• KPV — Synergistic: Both have anti-inflammatory properties through different pathways (VIP via VPAC receptors, KPV via melanocortin system)
• Selank — Compatible: Both have anxiolytic and immunomodulatory effects through different receptor systems
• DSIP — Compatible: Both involved in circadian regulation - VIP in suprachiasmatic nucleus, DSIP in sleep induction
• Cerebrolysin — Similar: Cerebrolysin contains VIP-like peptide fragments. Both are neuroprotective with overlapping mechanisms
• GHK-Cu — Compatible: Complementary - VIP for systemic immune regulation, GHK-Cu for tissue remodeling and copper delivery

Days 1-7: May experience mild nasal irritation initially. Week 1-2: Potential improvement in energy and sleep quality. Week 2-4: Reduction in inflammatory symptoms. Week 4-8: Progressive improvement in CIRS markers if applicable. Month 2+: Continued correction of inflammatory and neurological parameters. Note: Full benefits in CIRS may take several months of consistent use.

First dose should be administered under medical supervision with lab monitoring. Pre-VIP labs: TGF-β1, Lipase (baseline). Post-VIP 15 min labs: TGF-β1, Lipase (to assess response and safety). Stop immediately if abdominal pain develops or lipase elevates above range. Not FDA-approved as nasal spray - compounded off-label. CIRS patients: Complete Shoemaker Protocol steps 1-11 before starting VIP. Ensure MARCoNS eradicated and environment safe before VIP therapy. Monitor blood pressure - VIP can cause vasodilation. Not recommended during pregnancy or breastfeeding.

First dose should be administered under medical supervision with lab monitoring. Pre-VIP labs: TGF-β1, Lipase (baseline). Post-VIP 15 min labs: TGF-β1, Lipase (to assess response and safety). Stop immediately if abdominal pain develops or lipase elevates above range. Not FDA-approved as nasal spray - compounded off-label. CIRS patients: Complete Shoemaker Protocol steps 1-11 before starting VIP. Ensure MARCoNS eradicated and environment safe before VIP therapy. Monitor blood pressure - VIP can cause vasodilation. Not recommended during pregnancy or breastfeeding.

VIP should be stored at Fridge 2-8°C.